10 Best Gene Therapy Stocks to Buy in 2026
In this article, we will discuss the 10 Best Gene Therapy Stocks to Buy in 2026.
4D Molecular Therapeutics Inc. (FDMT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 5,049,779 | $67,162,061 | 0.58% | |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,879,289 | $38,294,544 | 0.98% | |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 2,249,203 | $29,914,400 | +41% | 0.04% |
| 4. | Trails Edge Capital Partners Ortav (Tavi) Yehudai | 2,227,917 | $29,631,296 | +71% | 4.7% |
| 5. | Armistice Capital Steven Boyd | 2,000,000 | $26,600,000 | 0.33% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 850,000 | $13,600,000.00 | 4,787,914 | 2023-05-09 | Filing | |
| $23.00 | 1,100,000 | $25,300,000.00 | 3,937,914 | 2020-12-15 | Filing | |
| $23.00 | 100,000 | $2,300,000.00 | 100,000 | 2020-12-15 | Filing | |
| $23.00 | 4,347 | $99,981.00 | 4,347 | 2020-12-15 | Filing | |
| $23.00 | 425,000 | $9,775,000.00 | 1,060,880 | 2020-12-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.65 | 1,635 | $22,317.75 | 8,617 | 2026-09-16 | Filing | |
| $13.90 | 58,333 | $811,003.70 | 767,486 | 2026-09-14 | Filing | |
| $14.00 | 584 | $8,176.00 | 8,617 | 2026-09-01 | Filing | |
| $16.42 | 25,927 | $425,651.34 | 825,819 | 2026-08-19 | Filing | |
| $15.36 | 43,149 | $662,621.93 | 851,746 | 2026-08-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,746,289 | $76,465,835 | 0.03% | |
| 2. | 4,546,059 | $60,462,583 | 0% | |
| 3. | 4,258,668 | $56,640,284 | 0% | |
| 4. | 3,249,178 | $43,214,067 | 2.51% | |
| 5. | 2,911,109 | $38,717,750 | 0% |
News See All
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the top gene therapy stocks to buy according to hedge funds. 4D Molecular Therapeutics, Inc.
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
In this article, we will look at the Top 10 Gene Therapy Stocks to Buy According to Hedge Funds.
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The fifteenth stock that takes place on our list is 4D Molecular Therapeutics, Inc.
20 Best Biotech Stocks Under $20 to Buy Now
In this article, we will be taking a look at the 20 Best Biotech Stocks Under $20 to Buy Now. The U.S.
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D Molecular Therapeutics, Inc.
13 Best Get Rich Fast Stocks to Buy Right Now
In this article, we will take a look at the Best Get Rich Fast Stocks to Buy Right Now.
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is one of the hot stocks to buy with huge upside potential.
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Jim Cramer Answered Questions About These 10 Stocks Recently
On Tuesday’s episode of Mad Money, host Jim Cramer, with the help of commodity broker and futures analyst Carley Garner’s interpretation of charts, raised caution over potential warning signs developing...
Hedge Fund Resource Center